Noxopharm Limited
ASX:NOX.AX
0.135 (AUD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.4 | 6.01 | 5.429 | 5.608 | 8.282 | 3.751 | 0.917 | 0.126 | 0 |
| Cost of Revenue
| 2.935 | 0.155 | 0.262 | 0.262 | 0.241 | 0.062 | 0.059 | 0.03 | 0.003 |
| Gross Profit
| -0.535 | 5.856 | 5.167 | 5.347 | 8.041 | 3.689 | 0.858 | 0.096 | -0.003 |
| Gross Profit Ratio
| -0.223 | 0.974 | 0.952 | 0.953 | 0.971 | 0.983 | 0.936 | 0.76 | 0 |
| Reseach & Development Expenses
| 2.935 | 10.647 | 7.777 | 6.969 | 7.333 | 6.616 | 4.113 | 0.816 | 0.143 |
| General & Administrative Expenses
| 1.041 | 1.477 | 1.665 | 1.594 | 3.045 | 8.092 | 4.935 | 1.798 | 0.298 |
| Selling & Marketing Expenses
| 0.058 | 0.192 | 0.104 | 0.129 | 0.124 | 0.351 | 0.234 | 0.161 | 0.258 |
| SG&A
| 4.065 | 5.794 | 7.169 | 7.379 | 8.792 | 8.988 | 6.329 | 1.96 | 0.557 |
| Other Expenses
| 0 | 1.557 | -3.429 | 13.955 | 19.918 | 3.572 | -7.637 | 0.126 | 0 |
| Operating Expenses
| 7 | 16.441 | 14.946 | 14.348 | 16.125 | 15.604 | 10.442 | 3.24 | 0.7 |
| Operating Income
| -7.535 | -16.595 | -15.208 | -14.61 | -16.366 | -15.666 | -10.501 | -3.24 | -0.703 |
| Operating Income Ratio
| -3.139 | -2.761 | -2.801 | -2.605 | -1.976 | -4.177 | -11.457 | -25.651 | 0 |
| Total Other Income Expenses Net
| 3.957 | -4.446 | -8.827 | 6.304 | 8.13 | -0.657 | -8.73 | 0.126 | -0.002 |
| Income Before Tax
| -3.578 | -21.041 | -24.034 | -8.306 | -8.236 | -16.323 | -19.231 | -3.046 | -0.705 |
| Income Before Tax Ratio
| -1.491 | -3.501 | -4.427 | -1.481 | -0.994 | -4.352 | -20.982 | -24.117 | 0 |
| Income Tax Expense
| -2.4 | -5.985 | -5.368 | 1.041 | -8.332 | -3.751 | -0.911 | -0.194 | 0 |
| Net Income
| -3.578 | -15.056 | -18.667 | -9.347 | -0.272 | -11.223 | -18.284 | -3.046 | -0.705 |
| Net Income Ratio
| -1.491 | -2.505 | -3.439 | -1.667 | -0.033 | -2.992 | -19.949 | -24.117 | 0 |
| EPS
| -0.012 | -0.052 | -0.064 | -0.035 | -0.002 | -0.081 | -0.15 | -0.035 | -0.021 |
| EPS Diluted
| -0.012 | -0.052 | -0.064 | -0.035 | -0.002 | -0.081 | -0.15 | -0.035 | -0.021 |
| EBITDA
| -4.6 | -16.441 | -14.946 | -14.348 | -16.125 | -15.604 | -10.442 | -3.209 | -0.7 |
| EBITDA Ratio
| -1.916 | -2.735 | -2.753 | -2.558 | -1.947 | -4.16 | -11.393 | -25.411 | 0 |